Understanding intravitreal injections: A guide for your eye health

Written by: Mr Vaughan Tanner
Published: | Updated: 26/09/2023
Edited by: Conor Dunworth

Intravitreal injections have gained popularity in recent years, but what exactly are they, and how do they work? In this article, renowned consultant ophthalmic surgeon Mr Vaughan Tanner delves into the world of intravitreal injections, answering some of the most commonly searched questions to help you better understand this important aspect of eye care.

 

What are intravitreal injections?

Intravitreal injections are a medical procedure in which medication is directly injected into the vitreous humour, the jelly-like substance that fills the middle of the eye. These injections are typically administered to treat various eye conditions, including age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and some other retinal disorders.

 

How do intravitreal injections work?

Intravitreal injections work by delivering a precise dose of medication directly to the affected area within the eye. By bypassing the digestive system and bloodstream, this method ensures that a higher concentration of the medication reaches the target tissue, maximising its therapeutic effects.

 

What medications are used in intravitreal injections?

The most common medications used in intravitreal injections include anti-vascular endothelial growth factor (anti-VEGF) drugs. These medications help combat abnormal blood vessel growth and leakage in the eye, which are common in conditions like AMD and diabetic retinopathy.

 

Are intravitreal injections painful?

Many people are concerned about the discomfort associated with intravitreal injections. The procedure is typically well-tolerated, with minimal pain. Before the injection, an anaesthetic eye drop is applied to numb the eye's surface, ensuring that you won't feel significant pain during the procedure. Some patients may experience mild discomfort or pressure, but this usually lasts only a short time.

 

How often are intravitreal injections needed?

The frequency of intravitreal injections varies depending on the underlying eye condition and its severity. Typically, these injections are given on a monthly or bimonthly basis initially. Your ophthalmologist will determine the most appropriate schedule for your specific case, and it may be adjusted over time based on your response to treatment.

 

What are the potential risks and side effects?

While intravitreal injections are generally safe and effective, like any medical procedure, they carry some risks. Potential side effects may include infection, retinal detachment, or elevated eye pressure. It's essential to discuss these risks with your eye specialist before starting treatment.

 

What can I expect after an intravitreal injection?

After an intravitreal injection, you may experience some temporary blurriness or floaters in your vision. These effects typically resolve within a few days. It's crucial to follow your doctor's post-injection care instructions, which may include avoiding strenuous activities and refraining from rubbing your eyes.

 

Are intravitreal injections a cure?

Intravitreal injections are not a cure for the underlying eye conditions they treat. Instead, they help manage and stabilise the condition, preventing further vision loss and sometimes even improving vision. Regular follow-up appointments with your ophthalmologist are essential to monitor your progress and adjust your treatment plan as needed.

 

If you would like to book a consultation with Mr Vaughan Tanner, you can do so today via his Top Doctors profile.

By Mr Vaughan Tanner
Ophthalmology

Mr Vaughan Tanner has over 20 years experience as a senior consultant ophthalmic surgeon to The Royal Berkshire Hospital, Reading and King Edward VII Hospital, Windsor. During that time, he led the Berkshire-wide vitreo-retinal surgical service, established a sub-specialist age-related macular degeneration service, provided a micro-incision cataract service and headed a general ophthalmic team providing care for acute and routine eye conditions. He now focuses on providing a private practice, centre of excellence for both cataract and retinal surgery. His subspecialist interests and recent advances include the introduction of sub-2mm micro-incision cataract extraction with multifocal and toric lens implants designed to significantly reduce spectacle dependence following cataract surgery.
 
He has also developed sutureless small incision vitrectomy techniques for the repair of retinal detachment, epiretinal membrane, macular hole and other vitreoretinal diseases. Mr Tanner’s extensive surgical experience includes the performance or supervision of over 15,000 major intraocular cataract and retinal procedures.

Mr Tanner has led the introduction of many new retinal treatments including Faricimab, Lucentis, Eylea anti-growth factor, intravitreal injections and Ozurdex steroid implants. These innovations have significantly improved vision for many patients suffering from age-related macular degeneration, diabetic retinopathy, retinal vein occlusion and other retinal problems.

In the private sector, he has developed a comprehensive service aiming to provide the highest level of personal care using the latest surgical techniques available. His main practice covers Berkshire, Oxfordshire, Surrey, Buckinghamshire, Hampshire and London with many national and international referrals. Private consultations and treatments are available at the following The Princess Margaret Hospital, Windsor, Dunedin Hospital, Reading and Circle Hospital, Reading.

His undergraduate study was at St George’s Hospital Medical School, London where he was awarded Medical Research Council funding in addition to his medical degree. His completion of higher surgical training at the Oxford Eye Hospital led to the award of the Fellowship of the Royal College of Ophthalmologists. He then completed three years of advanced, sub-specialist fellowships at both Moorfields Eye Hospital, London and St Thomas’ Hospital, London. During this period he gained expertise in the surgical and medical management of all retinal disorders including macular surgery. He has co-authored “Diseases of the Ocular Fundus” which was awarded first prize as “Best Authored Post Graduate Textbook” by the Royal Society of Medicine and the Royal Society of Authors. He has previously hosted both the Southern and National Annual Meetings of the British and Eire Association of Vitreo-Retinal Surgeons. He is an invited scientific reviewer for the British Journal of Ophthalmology.

Furthermore, Mr Tanner was a consultant clinical supervisor for The Oxford Deanery School of Ophthalmology responsible for post-graduate training and also led a fellowship training programme in advanced vitreo-retinal surgical techniques for surgeons becoming consultants in this sub-specialty. He has previously been appointed both lead clinician and clinical governance lead for the ophthalmology department, Royal Berkshire Hospital and has been awarded three NHS clinical excellence awards. He is currently appointed ophthalmology lead for the Medical Advisory Committee at Princess Margaret Hospital, Windsor.

View Profile

Overall assessment of their patients


  • Related procedures
  • Microdermoabrasion
    Microneedling
    Dark circles
    Mesotherapy
    Facelift
    Neck lift
    Botulinum toxin (Botox™)
    Dermal fillers
    Peeling
    Facial paralysis
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.